Halozyme Therapeutics (NASDAQ:HALO) Posts Earnings Results, Beats Expectations By $0.02 EPS

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02, Zacks reports. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million.

Halozyme Therapeutics Trading Up 0.5 %

Shares of Halozyme Therapeutics stock traded up $0.31 on Friday, hitting $57.75. 1,299,523 shares of the company traded hands, compared to its average volume of 1,313,186. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a market cap of $7.11 billion, a PE ratio of 16.84, a PEG ratio of 0.44 and a beta of 1.25. The stock's 50 day moving average price is $53.46 and its 200-day moving average price is $54.62. Halozyme Therapeutics has a 52 week low of $37.73 and a 52 week high of $65.53.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on HALO shares. HC Wainwright lifted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Benchmark reissued a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company's stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.